Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Ligustrazine Phosphate for Injection

Approved

化学药品

Ligustrazine Phosphate for Injection

吉林省辉南长龙生化药业股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Feb 20, 2021
Approval ID: 7LeaeWWuOGS
Company: 吉林省辉南长龙生化药业股份有限公司
Type: 化学药品

Approval Details

Approval Id: 7LeaeWWuOGS
Approval Number: 国药准字H20040655
Generic Name: 注射用磷酸川芎嗪
Generic Name En: Ligustrazine Phosphate for Injection
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 50mg
Reg Date: 2021-02-20
Company Name: 吉林省辉南长龙生化药业股份有限公司
Company Address: 吉林省辉南县朝阳镇北山街31号
Company Detail Path: /organization/jilin-changlong

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Feb 20, 2021

Approval ID

7LeaeWWuOGS

Type

化学药品

Back to NMPA Approvals

注射用磷酸川芎嗪 - NMPA Drug Approval Details